ConductScience.org, home

Disease · MONDO_0002158

Targets298

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
KDRVascular endothelial growth factor receptor18Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitorPhase 3https://conductscience.org/library/genes/3791Drugs and targets
FLT4Vascular endothelial growth factor receptor15Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitorPhase 3https://conductscience.org/library/genes/2324Drugs and targets
FLT1Vascular endothelial growth factor receptor14Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitorPhase 3https://conductscience.org/library/genes/2321Drugs and targets
KITMast/stem cell growth factor receptor Kit13Stem cell growth factor receptor inhibitorPhase 3https://conductscience.org/library/genes/3815Drugs and targets
PDGFRBPlatelet-derived growth factor receptor13Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitorPhase 3https://conductscience.org/library/genes/5159Drugs and targets
TUBA1ATubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/7846Drugs and targets
TUBA1BTubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/10376Drugs and targets
TUBA1CTubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/84790Drugs and targets
TUBA3CTubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/7278Drugs and targets
TUBA3ETubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/112714Drugs and targets
TUBA4ATubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/7277Drugs and targets
TUBBTubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/203068Drugs and targets
TUBB1Tubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/81027Drugs and targets
TUBB2ATubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/7280Drugs and targets
TUBB2BTubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/347733Drugs and targets
TUBB3Tubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/10381Drugs and targets
TUBB4ATubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/10382Drugs and targets
TUBB4BTubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/10383Drugs and targets
TUBB6Tubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/84617Drugs and targets
TUBB8Tubulin13Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliserPhase 3https://conductscience.org/library/genes/347688Drugs and targets

diseases-2026-09-18-0.1.0

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002158/targets